NCT01444404View on ClinicalTrials.gov

A Study of AMG 820 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

February 6, 2014

Study Completion Date

February 6, 2014

Conditions
Advanced MalignancyAdvanced Solid TumorsCancerOncologyOncology PatientsTumors
Interventions
DRUG

AMG 820

AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.

Trial Locations (3)

19111

Research Site, Philadelphia

29605

Research Site, Greenville

78229

Research Site, San Antonio

Sponsors

Lead Sponsor

AmMax Bio, Inc.
All Listed Sponsors
lead

AmMax Bio, Inc.

INDUSTRY

NCT01444404 - A Study of AMG 820 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter